혈액제재 시장 보고서 : 제품별, 항혈전 및 항응고 유형별, 항혈전 및 항응고 적응별, 지역별(2025-2033년)

The global blood preparation market size reached USD 46.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 66.9 Billion by 2033, exhibiting a growth rate (CAGR) of 3.98% during 2025-2033. The market is expanding due to the rising prevalence of chronic diseases, imposition of government initiatives that improve healthcare infrastructure, growing public awareness leading to increased blood donations, rapid advancements in blood processing technology, and the increasing adoption of personalized medicine.

Blood Preparation Market Trends:

Increasing Prevalence of Chronic Diseases

The rise in chronic diseases, including cardiovascular conditions, cancer, and diabetes, is one of the major factors positively impacting the blood preparation market dynamics. As per industry research, an estimated 129 million people in the U.S. have at least one major chronic disease. These diseases are known to result in complications such as anemia, clotting disorders, and immune system deficiencies, which require frequent blood transfusions, platelet replacement therapy, and plasma treatments. For instance, according to the National Blood Collection and Utilization Survey (NBCUS) report, in 2021, 10,764,000 units of whole blood-derived and apheresis red blood cells (RBCs) were transfused in the United States. Moreover, the growing geriatric population across the globe, exacerbating the need for blood transfusion as these individuals are more prone to chronic illnesses and associated complications, is bolstering the expansion of this industry.

Introduction of Government Initiatives and Healthcare Infrastructure Development

The introduction of various government initiatives to improve healthcare infrastructure and ensure a stable blood supply is enhancing the blood preparation market size. The increasing government focus on investing in initiatives that promote blood donation, improve blood bank facilities, and enhance the overall safety and availability of blood products is boosting the market growth. For instance, the Government of India (GOI), through blood transfusion services, has been supporting 1131 blood banks in the public and charitable sector with respect to manpower, procurement of blood bags and testing kits, conduction of voluntary blood donation (VBD) camps, and information education communication (IEC) activities. In addition, governments are implementing stringent measures to ensure the quality and safety of blood products, which helps build trust among healthcare providers and patients. For example, e-RaktKosh, an initiative of the Government of India to monitor the blood banks, is an integrated blood bank management information system that interconnects all the blood banks into a single network.

Growing Awareness and Increasing Blood Donations

The growing awareness about the importance of blood donation and the increasing number of blood donors across the globe are boosting the blood preparation market share. Each year, an estimated 6.8 million people in the U.S. donate blood, and 13.6 million units of whole blood and red blood cells are collected. Moreover, the introduction of public health campaigns and initiatives led by governments, non-governmental organizations (NGOs), and healthcare providers to educate the public about the life-saving importance of donating blood is bolstering the market growth. Along with this, the growing demand for blood products in developed and developing countries that is leading to more structured and organized blood donation systems, which ensure a steady and reliable supply of blood, is fueling the market growth.

Blood Preparation Market Segmentation:

Breakup by Product:

• Whole Blood
  • Red Cells
  • Granulocytes
  • Plasma
  • Platelets
• Blood Components
  • Whole Blood Components
  • Packed Red Cells
  • Leukocyte Reduced Red Blood Cells
  • Frozen Plasma
  • Platelet Concentrate
  • Cryoprecipitate
• Blood Derivatives

Whole blood accounts for the majority of the market share

As per the blood preparation market analysis, whole blood dominated the market due to its widespread use in various medical treatments, including surgeries, trauma care, and transfusions for patients with severe anemia or blood loss. Moreover, it contains all essential components, such as red cells, white cells, platelets, and plasma, making it versatile for multiple clinical applications. Besides this, the growing demand for whole blood in emergency and critical care settings, coupled with its crucial role in life-saving procedures, is contributing to the market growth.

Breakup by Antithrombotic and Anticoagulants Type:

• Platelet Aggregation Inhibitors
  • Glycoprotein Inhibitors
  • COX Inhibitors
  • ADP Antagonists
  • Others
• Fibrinolytics
  • Tissue Plasminogen Activator (TPA)
  • Streptokinase
  • Urokinase
• Anticoagulants
  • Heparins
  • Vitamin K Antagonists
  • Direct Thrombin Inhibitors
  • Direct Factor Xa Inhibitors

Anticoagulants holds the largest share of the industry

Based on the blood preparation market overview, anticoagulants accounted for the largest market, driven by their critical role in preventing and treating blood clots, which are common in conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. Moreover, anticoagulants are essential for managing clot-related disorders and reducing the risk of strokes and heart attacks. Besides this, their frequent use in surgical procedures and long-term treatments for patients with cardiovascular conditions is enhancing the market growth. Along with this, the increasing geriatric population, which is more prone to clotting disorders, and the development of newer anticoagulant therapies that offer improved safety and efficacy profiles are boosting the blood preparation market growth rate.

Breakup by Antithrombotic and Anticoagulants Application:

• Thrombocytosis
• Pulmonary Embolism
• Renal Impairment
• Angina Blood Vessel Complications
• Others

Thrombocytosis represents the leading market segment

According to the blood preparation market forecast, thrombocytosis represented the largest share in the market, due to the increasing prevalence of conditions that cause elevated platelet counts, such as myeloproliferative disorders. Moreover, thrombocytosis often leads to excessive blood clot formation, which can result in severe complications like strokes or heart attacks. Anticoagulants and antithrombotic therapies are critical for managing this condition by preventing abnormal clotting. Along with this, the growing awareness of thrombocytosis, rapid advancements in diagnostic tools, and the availability of targeted anticoagulant treatments are driving the market growth.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest blood preparation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for blood preparation.

As per the blood preparation market report, North America is leading the market, driven by its well-established healthcare infrastructure, high prevalence of chronic diseases, and significant healthcare spending. Moreover, the growing demand for blood products, fueled by the growing incidence of conditions such as cancer, cardiovascular diseases, and anemia, which require regular blood transfusions and platelet therapies, is bolstering the market growth. Besides this, the introduction of advanced medical technologies, a strong emphasis on blood safety, and a large network of blood donation centers in the region are acting as major blood preparation market drivers.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the blood preparation industry include Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., LEO Pharma A/S, Pfizer Inc., Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.), Sanofi S.A., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• The leading players in the market are focusing on strategic collaborations, product innovations, and expanding their geographical presence to strengthen their market positions. They are investing in research and development (R&D) to introduce advanced blood products and technologies aimed at improving safety and efficacy. Moreover, several firms are enhancing their production capabilities to meet the rising demand for plasma-derived therapies and other blood components. Besides this, they are forming partnerships with hospitals, blood banks, and healthcare institutions to secure stable supply chains and improve accessibility.

Key Questions Answered in This Report

• 1.What was the size of the global blood preparation market in 2024?
• 2.What is the expected growth rate of the global blood preparation market during 2025-2033?
• 3.What are the key factors driving the global blood preparation market?
• 4.What has been the impact of COVID-19 on the global blood preparation market?
• 5.What is the breakup of the global blood preparation market based on the product?
• 6.What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants type?
• 7.What is the breakup of the global blood preparation market based on the antithrombotic and anticoagulants application?
• 8.What are the key regions in the global blood preparation market?
• 9.Who are the key players/companies in the global blood preparation market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Blood Preparation Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Whole Blood
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Red Cells
    • 6.1.2.2 Granulocytes
    • 6.1.2.3 Plasma
    • 6.1.2.4 Platelets
  • 6.1.3 Market Forecast
• 6.2 Blood Components
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Whole Blood Components
    • 6.2.2.2 Packed Red Cells
    • 6.2.2.3 Leukocyte Reduced Red Blood Cells
    • 6.2.2.4 Frozen Plasma
    • 6.2.2.5 Platelet Concentrate
    • 6.2.2.6 Cryoprecipitate
  • 6.2.3 Market Forecast
• 6.3 Blood Derivatives
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Antithrombotic and Anticoagulants Type

• 7.1 Platelet Aggregation Inhibitors
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Glycoprotein Inhibitors
    • 7.1.2.2 COX Inhibitors
    • 7.1.2.3 ADP Antagonists
    • 7.1.2.4 Others
  • 7.1.3 Market Forecast
• 7.2 Fibrinolytics
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Tissue Plasminogen Activator (TPA)
    • 7.2.2.2 Streptokinase
    • 7.2.2.3 Urokinase
  • 7.2.3 Market Forecast
• 7.3 Anticoagulants
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Heparins
    • 7.3.2.2 Vitamin K Antagonists
    • 7.3.2.3 Direct Thrombin Inhibitors
    • 7.3.2.4 Direct Factor Xa Inhibitors
  • 7.3.3 Market Forecast

8 Market Breakup by Antithrombotic and Anticoagulants Application

• 8.1 Thrombocytosis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pulmonary Embolism
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Renal Impairment
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Angina Blood Vessel Complications
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Baxter International Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Boehringer Ingelheim International GmbH
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bristol-Myers Squibb Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Daiichi Sankyo Company Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 GlaxoSmithKline PLC
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Johnson & Johnson Services Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 LEO Pharma A/S
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Portola Pharmaceuticals Inc. (Alexion Pharmaceuticals Inc.)
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Sanofi S.A.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis